RAD21高表达预示着接受手术治疗的非小细胞肺癌患者预后不良。
High expression of RAD21 predicts poor survival in patients with operated non-small-cell lung cancer.
作者信息
Zhu Tao, Gao Zhaojia, Yuan Kai, Wang Yong
机构信息
Division of Thoracic Surgery, The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, Jiangsu Province, China.
Heart and Lung Disease Laboratory, The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, Jiangsu Province, China.
出版信息
Tumori. 2020 Mar 17:300891620910805. doi: 10.1177/0300891620910805.
PURPOSE
To investigate the expression profile and prognostic value of RAD21 in patients with non-small cell lung cancer (NSCLC).
METHODS
A tissue microarray (TMA) containing 60 paired NSCLC tissues and peritumor tissues was purchased and another TMA containing 140 NSCLC tissues was constructed. Then, immunohistochemical staining was performed and scored. Finally, the expression profile and prognostic value of RAD21 were evaluated.
RESULTS
RAD21 was predominantly detected in the nucleus of tumor and peritumor cells. RAD21 was more highly expressed in tumor tissues compared to peritumor tissues. High RAD21 expression was correlated with more lymph node metastases and advanced pathological stage, but not with any other clinicopathological features. High RAD21 expression led to worsened overall survival (OS) and was an independent prognostic factor for worsened OS in NSCLC, especially in stage II-III.
CONCLUSION
High RAD21 expression indicates poor survival in patients with NSCLC. RAD21 may become a novel prognostic biomarker and therapeutic target in patients with NSCLC.
目的
探讨RAD21在非小细胞肺癌（NSCLC）患者中的表达谱及预后价值。
方法
购买包含60对NSCLC组织及瘤周组织的组织芯片（TMA），并构建另一个包含140例NSCLC组织的TMA。然后，进行免疫组织化学染色并评分。最后，评估RAD21的表达谱及预后价值。
结果
RAD21主要在肿瘤细胞和瘤周细胞的细胞核中检测到。与瘤周组织相比，RAD21在肿瘤组织中表达更高。RAD21高表达与更多的淋巴结转移和更高的病理分期相关，但与任何其他临床病理特征无关。RAD21高表达导致总生存期（OS）恶化，并且是NSCLC患者OS恶化的独立预后因素，尤其是在II-III期。
结论
RAD21高表达表明NSCLC患者预后不良。RAD21可能成为NSCLC患者新的预后生物标志物和治疗靶点。
Zotero 插件